Boston Scientific (BSX) shares were in focus Wednesday after the medical device manufacturer reported third quarter results that were in line with analysts expectations. The company reported earnings of $0.27 a share, in line with expectations. Revenue of $2.11 billion, surpassed Wall Street's expectations of $2.07 billion
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.